VASH1 and lung carcinoma: In lung cancer, Wang et al. have shown that METTL3 targets miR-143-3p to enhance its biogenesis, leading to the silencing of vasohibin-1 (VASH1) and subsequent increased angiogenesis and blood–brain barrier invasion capability, finally promoting brain metastasis [227].